Shire PLC’s (SHPG) Buy Rating Reiterated at Goldman Sachs Group Inc.
Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reissued by research analysts at Goldman Sachs Group Inc. in a research note issued on Sunday.
Other analysts also recently issued research reports about the stock. Piper Jaffray Cos. set a $201.00 price target on shares of Shire PLC and gave the company a “hold” rating in a research note on Saturday, October 1st. Leerink Swann reaffirmed a “buy” rating on shares of Shire PLC in a research note on Saturday, October 1st. Jefferies Group reaffirmed a “buy” rating on shares of Shire PLC in a research note on Friday, July 1st. BTIG Research reaffirmed a “buy” rating and set a $230.00 price target on shares of Shire PLC in a research note on Tuesday, July 12th. Finally, RBC Capital Markets reaffirmed an “outperform” rating on shares of Shire PLC in a research note on Wednesday, August 3rd. Five investment analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $228.15.
Shire PLC (NASDAQ:SHPG) opened at 187.70 on Friday. The company has a 50-day moving average price of $194.68 and a 200 day moving average price of $187.77. The company has a market capitalization of $55.91 billion, a PE ratio of 39.01 and a beta of 1.16. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.35. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. The firm earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. During the same quarter in the previous year, the firm posted $2.63 earnings per share. The company’s revenue was up 55.9% on a year-over-year basis. Equities research analysts anticipate that Shire PLC will post $12.92 earnings per share for the current year.
The business also recently disclosed a dividend, which was paid on Friday, October 7th. Stockholders of record on Friday, September 9th were issued a dividend of $0.139 per share. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s dividend payout ratio (DPR) is presently 15.63%.
Large investors have recently made changes to their positions in the stock. Duff & Phelps Investment Management Co. bought a new stake in shares of Shire PLC during the third quarter worth $3,332,000. Capstone Asset Management Co. raised its stake in shares of Shire PLC by 6.7% in the third quarter. Capstone Asset Management Co. now owns 31,076 shares of the biopharmaceutical company’s stock worth $6,024,000 after buying an additional 1,959 shares during the period. Fox Run Management L.L.C. bought a new stake in shares of Shire PLC during the third quarter worth $349,000. Atria Investments LLC raised its stake in shares of Shire PLC by 171.2% in the third quarter. Atria Investments LLC now owns 3,450 shares of the biopharmaceutical company’s stock worth $669,000 after buying an additional 2,178 shares during the period. Finally, Eagle Asset Management Inc. bought a new stake in shares of Shire PLC during the third quarter worth $294,000. 24.26% of the stock is currently owned by hedge funds and other institutional investors.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.